Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 4, 2012, Pages 1465-1477

  Guerrant, William ^a   Patil, Vishal ^a   Canzoneri, Joshua C ^a   Oyelere, Adegboyega K ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN DERIVATIVE; GYRASE INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N BENZYL DOXORUBICIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL-FREE SYSTEM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE INHIBITORS; TUBULIN;

EID: 84857406206     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200799p     Document Type: Article

References (71)

1. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651 (Pubitemid 38981718)
2. Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm J. Med. Chem. 2005, 48, 6523-6543 (Pubitemid 41504710)
3. Frantz, S. Drug discovery: playing dirty Nature 2005, 437, 942-943
4. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nature Rev. Drug Discovery 2004, 3, 353-359 (Pubitemid 38499762)
5. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136 (Pubitemid 43221881)
6. Cmeserly, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design Trends Pharmacol. Sci. 2005, 26, 178-182 (Pubitemid 40432652)
7. Fray, M. J.; Bish, G.; Brown, A. D.; Fish, P. V.; Stobie, A.; Wakenhut, F.; Whitlock, G. A. N -(1,2-Diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor Bioorg. Med. Chem. Lett. 2006, 16, 4345-4348
8. Neumeyer, J. L.; Peng, X.; Knapp, B. I.; Bidlack, J. M.; Lazarus, L. H.; Salvadori, S.; Trapella, C.; Balboni, G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores J. Med. Chem. 2006, 49, 5640-5643 (Pubitemid 44373197)
9. Jones, P. A.; Baylin, S. B. The epigenomics of cancer Cell 2007, 128, 683-692 (Pubitemid 46273572)
10. Kouzarides, T. Chromatin modifications and their function Cell 2007, 128, 693-705 (Pubitemid 46273577)
11. Shilatifard, A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression Annu. Rev. Biochem. 2006, 75, 243-269 (Pubitemid 44118033)
12. Ropero, S; Esteller, M. The role of histone deacetylases (HDACs) in human cancer Mol. Oncol. 2007, 1, 19-25 (Pubitemid 46776612)
13. Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 2000, 92, 1210-1216 (Pubitemid 30627729)
14. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumor activity against human tumors Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4592-4597 (Pubitemid 29190381)
15. Glick, R. D.; Swindemen, S. L.; Coffey, D. C.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; La Quaglia, M. P. Hybrid polar histone deacetylase induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma Cancer Res. 1999, 59, 4392-4399 (Pubitemid 29418759)
16. Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res. 2000, 60, 5165-5170
17. Oyelere, A. K.; Chen, P. C.; Guerrant, W.; Mwakwari, S. C.; Hood, R.; Zhang, Y.; Fan, Y. Non-peptide macrocyclic histone deacetylases inhibitors J. Med. Chem. 2009, 52, 456-468
18. Gu, W; Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 1997, 90, 595-606 (Pubitemid 27357952)
19. Martinez-Balbás, M. A.; Bauer, U. M.; Nielsen, S. J.; Brehm, A.; Kouzarides, T. Regulation of E2F1 activity by acetylation EMBO J. 2000, 19, 662-671 (Pubitemid 30093739)
20. Marzio, G.; Wagener, C.; Gutierrez, M. I.; Cartwright, P.; Helin, K.; Giacca, M. E2F family members are differentially regulated by reversible acetylation J. Biol. Chem. 2000, 275, 10887-10892 (Pubitemid 30212722)
21. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, T. P. HDAC6 is a microtubule-associated deacetylase Nature 2002, 417, 455-458 (Pubitemid 34563539)
22. Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.; Wu, J. T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol. Cell 2005, 18, 601-607 (Pubitemid 40726236)
23. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Padzur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 2007, 12, 1247-1252 (Pubitemid 350106355)
24. Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R. W.; Gardner, E. R.; Figg, W. D.; Bates, S. E. Romidepsin; a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors Expert Rev. Anticancer Ther. 2010, 10, 997-1008
25. Mwakwari, S. C.; Patil, V.; Guerrant, W.; Oyelere, A. K. Macrocyclic histone deacetylases inhibitors Curr. Top. Med. Chem. 2010, 10, 1423-1440
26. Kelly, W. K; O'Connor, O. A.; Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials Expert. Opin. Invest. Drugs. 2002, 11, 1695-1713 (Pubitemid 35469917)
27. Rosato, R. R.; Grant, S. Histone deacetylase inhibitors in clinical development Expert Opin. Invest. Drugs 2004, 13, 21-38 (Pubitemid 38111432)
28. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future Nature Rev. Drug Discovery 2006, 5, 37-50
29. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193 (Pubitemid 29436325)
30. Wang, D.-F.; Wiest, O.; Helquist, P.; Lan-Hargest, H-Y; Wiech, N. L. On the function of the 14 Å long internal cavity of histone deacetylase-like protein: implication for the design of histone deacetylase inhibitors J. Med. Chem. 2004, 47, 3409-3417 (Pubitemid 38746091)
31. Chen, L.; Wilson, D.; Jayaram, H. N.; Pankiewicz, K. W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment J. Med. Chem. 2007, 50 (26) 6685-6691 (Pubitemid 350309105)
32. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of iminatib hybrids as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases J. Med. Chem. 2009, 52 (8) 2265-2279
33. Cai, X.; Zhai, H.-X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Cheng-Jung, L.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)- N -hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer J. Med. Chem. 2010, 53 (5) 2000-2009
34. Piccart-Gebhart, M. J. Anthracyclines and the tailoring of treatment for early breast cancer N. Engl. J. Med. 2006, 354, 2177-2179 (Pubitemid 43736618)
35. Kim, M. S.; Blake, M.; Baek, J. H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res. 2003, 63, 7291-7300 (Pubitemid 37413470)
36. Catalano, M. G.; Fortunati, N.; Pugliese, M.; Poli, R.; Bosco, O.; Mastrocola, R.; Aragno, M.; Bocuzzi, G. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells J. Endocrinol. 2006, 191 (2) 465-472 (Pubitemid 44830622)
37. Johnson, C. A.; Padget, K.; Austin, C. A.; Turner, B. M. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis J. Biol. Chem. 2001, 276 (7) 4539-4542
38. Marchion, D. C.; Bicaku, E.; Daud, A. I.; Richon, V.; Sullivan, D. M.; Munster, P. N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J. Cell Biochem. 2004, 92 (2) 223-237
39. Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 1984, 226, 466-468 (Pubitemid 14012819)
40. Binaschi, M.; Bigioni, M.; Cipollone, A.; Rossi, C.; Goso, C.; Maggi, C. A.; Capranico, G.; Animati, F. Anthracyclines: selected new developments Curr. Med. Chem. Anti-Cancer Agents 2001, 1 (2) 113-130
41. Pommier, Y.; Schwartz, R. E.; Kohn, K. W.; Zwelling, L. A. Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated nuclei by antineoplastic intercalating agents Biochemistry 1984, 23, 3194-3201 (Pubitemid 14056884)
42. Kiyomiya, K.; Matsuo, S.; Kurebe, M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus Life Sci. 1998, 62 (20) 1853-1860 (Pubitemid 28206670)
43. Kiyomiya, K.; Matsuo, S.; Kurebe, M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex Cancer Res. 2001, 61, 2467-2471 (Pubitemid 32685825)
44. Tong, G. L.; Wu, H. Y.; Smith, T. H.; Henry, D. W. Adriamycin analogs. 3. Synthesis of N -alkylated anthracyclines with enhanced efficacy and reduced toxicity J. Med. Chem. 1979, 22, 912-918 (Pubitemid 10235923)
45. Martín, B.; Vaquero, A.; Priebe, W.; Portugal, J. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiated in vitro Nucleic Acids Res. 1999, 27, 3402-3409 (Pubitemid 29414664)
46. Lothstein, L.; Israel, M.; Sweatman, T. W. Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road Drug Resist. Updates 2001, 4, 169-177 (Pubitemid 33089454)
47. Gate, L.; Couvreur, P.; Nguyen-Ba, G.; Tapiero, H. N -Methylation of anthracyclines modulates their cytotoxicity and pharmacokinetics in wild type and multidrug resistant cells Biomed. Pharmacother. 2003, 57, 301-308 (Pubitemid 37123102)
48. Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, M.; Oyelere, A. K. Non-peptide histone deacetylases inhibitors derived from tricyclic ketolide skeleton J. Med. Chem. 2010, 53, 6100-6111
49. Chen, P. C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A. K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group Bioorg. Med. Chem. 2008, 16, 4839-4853 (Pubitemid 351625900)
50. Lu, J.; Yoshida, O; Hayashi, S.; Arimoto, H. Synthesis of rigidly-linked vancomycin dimers and their in vivo efficacy against resistant bacteria Chem. Commun. 2007, 251-253 (Pubitemid 46052673)
51. 1 (S44HP), a genetically engineered anti-fungal polyene macrolide antibiotic J. Med. Chem. 2009, 52, 189-196
52. Yang, S.; Lagu, B.; Wilson, L. Mild and efficient lewis acid-promoted detritylation in the synthesis of N -hydroxy amides: a concise synthesis of (-)-cobactin T J. Org. Chem. 2007, 72 (21) 8123-8126 (Pubitemid 47582605)
53. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662 (Pubitemid 128590223)
54. Estiu, G.; Wiest, O. HDAC1 homology model. Personal Communication.
55. Marini, J. C.; Miller, K. G.; Englund, P. T. Decatenation of kinetoplast DNA by topoisomerases J. Biol. Chem. 1980, 255 (11) 4976-4979
56. Sahai, B; Kaplan, J. A quantitative decatenation assay for type II topoisomerases Anal. Biochem. 1986, 156 (2) 364-379 (Pubitemid 16051773)
57. Qu, X.; Wan, C.; Becker, H. C.; Zhong, D.; Zewail, A. H. The anticancer drug-DNA complex: femtosecond primary dynamics for anthracycline antibiotics function Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (25) 14212-14217 (Pubitemid 33121371)
58. Kulp, S. K.; Chen, C. S.; Wang, D. S.; Chen, C. Y.; Chen, C. S. Antitumor effects of a novel phenylbutyrate-based histone deacetylases inhibitor, (S)-HDAC-42, in prostate cancer Clin. Cancer Res. 2006, 12, 5199-5206 (Pubitemid 44453349)
59. Doyle, L. A.; Abruzzo, Y. W.; Krogmann, T.; Yongming, G.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670 (Pubitemid 29018757)
60. WAF1 expression and gene-associated histone acetylation Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (18) 10014-10019
61. Gartenhaus, R. B.; Wang, P.; Hoffmann, P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using the p53-dndependent pathway Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 265-268 (Pubitemid 26038140)
62. +-dependent tubulin deacetylase Mol. Cell 2003, 11, 437-444 (Pubitemid 36293837)
63. Schäfer, S.; Saunders, L.; Eliseeva, E.; Velena, A.; Jung, M.; Schwienhorst, A.; Strasser, A.; Dickmanns, A.; Ficner, R.; Schlimme, S.; Sippl, W.; Verdin, E.; Jung, M. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs) Bioorg. Med. Chem. 2008, 16, 2011-2033 (Pubitemid 351226567)
64. Namdar, M.; Perez, G.; Ngo, L.; Marks, P. A. Selective inhibition of histone deacetylases 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 20003-20008
65. Blagosklonny, M. V.; Robey, R.; Sackett, D. L.; Du, L.; Traganos, F.; Darzynkiewicz, Z.; Fojo, T.; Bates, S. E. Histone deacetylases inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Mol. Cell Ther. 2002, 1, 937-941
66. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO J. 2003, 22, 1168-1179 (Pubitemid 36313600)
67. Gao, H.; Huang, K. C.; Yamasaki, E. F.; Chan, K. K.; Chohan, L.; Snapka, R. M. XK469, a selective topoisomerase IIβ poison Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 12168-12173
68. Kiyomiya, K.; Satoh, J.; Horie, H.; Kurebe, M.; Nakagawa, H.; Matsuo, S. Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteosome Int. J. Oncol. 2002, 21 (5) 1081-1085
69. Marbeuf-Gueye, C.; Ettori, D.; Priebe, W.; Kozlowski, H.; Garnier-Suillerot, A. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein Biochim. Biophys. Acta 1999, 1450 (3) 374-384 (Pubitemid 29295487)
70. Klyatskaya, S. V.; Tretyakov, E. V.; Vasilevsky, S. F. Cross-coupling of aryl iodides with paramagnetic terminal acetylenes derived from 4,4,5,5-tetramethyl-2-imidazoline-1-oxyl 3-oxide Russ. Chem. Bull. 2002, 51, 128-134
71. Mai, A.; Esposito, M.; Sbardella, G.; Massa, S. A new facile and expeditious synthesis of N -hydroxy- N ′-phenyloctanediamide, a potent inducer of terminal cytodifferentiation Org. Prep. Proced. Int. 2001, 33 (4) 391-394